UPDATE: Nirsevimab 100 mg syringe shortage has resulted in updated guidance from the Centers for Disease Control and Prevention (CDC) for how to prioritize nirsevimab administration. Below is a summary of the interim guidance:
The 100 mg doses should be reserved for:
- Infants less than 6 months old
- Infants with underlying conditions that place them at highest risk for severe RSV disease
The CDC also recommends suspending nirsevimab dosing in palivizumab-eligible children 8-19 months old during the 2023-2024 RSV season. These children should receive palivizumab in alignment with the American Academy of Pediatrics (AAP) recommendations.
Due to the current availability of 50 mg doses, there are no changes to recommendations for patients who weigh less than 5 kg and all of these infants should receive nirsevimab. Avoid using 2 doses of the 50 mg syringes for patients eligible for the 100 mg dose, in order to preserve the 50 mg dose supply and prevent issues with reimbursement.
Background
Respiratory syncytial virus (RSV) is a common cause of respiratory illness in children and is the most common cause of hospitalization in infants. On July 17th, 2023 the FDA approved nirsevimab (BeyfortusTM), a monoclonal antibody indicated for the prevention of severe RSV for infants and select high risk children. On August 3rd, The Advisory Committee on Immunization Practices (ACIP) unanimously recommended the addition of nirsevimab to the Centers for Disease Control and Prevention’s (CDC’s) child immunization schedule and Vaccines for Children (VFC) program. The CDC recommends one dose of nirsevimab for all infants younger than 8 months, born during or entering their first RSV season. Additionally, it is recommended for children 8 to 19 months old who are at increased risk for severe RSV disease during their 2nd RSV season. Partners For Kids will update this page when new information and resources become available.
Partners For Kids Communication
Here you will find Partners For Kids developed content around RSV prevention, including
newsletter updates and webinars.
For Healthcare Professionals
This section contains links to reputable sources of information for health care professionals to learn more about nirsevimab and RSV-prevention.
- Nirsevimab supply chain issues – updated 10/17/2023
- VFC operation guide nirsevimab addendum from CDC – updated 12/1/2023
- Information about maternal RSV vaccination from CDC – updated 12/1/2023
- Nirsevimab recommendations from ACIP and AAP (Redbook)
- Nirsevimab in Morbidity Mortality Weekly Report from CDC
- Nirsevimab package insert
- Additional AAP resources
For Patients
These links are to patient facing websites and material that help to explain the importance of RSV-prevention and the recommendations for using nirsevimab.